Literature DB >> 25445160

Predictors of early stages of histological progression of branch duct IPMN.

Hiroshi Kurahara1, Kosei Maemura, Yuko Mataki, Masahiko Sakoda, Satoshi Iino, Yuko Kijima, Sumiya Ishigami, Shinichi Ueno, Hiroyuki Shinchi, Shoji Natsugoe.   

Abstract

BACKGROUND: An appropriate timing for surgical resection of branch duct-type intraductal papillary mucinous neoplasm (BD-IPMN) to achieve sufficient postoperative survival is still unknown.
METHODS: Of 80 patients with histologically proven IPMNs, 61 patients who had BD-IPMN without pancreatic cancer concomitant with IPMN were enrolled in this study. We divided BD-IPMN into four groups according to disease progression: low to intermediate grade of dysplasia (LGD/IGD-IPMN), high grade of dysplasia (HGD-IPMN), minimally invasive IPMN (MI-IPMN: T1a), and invasive IPMN (IN-IPMN: ≥T1b). Indicators of surgical resection were investigated on the basis of pathological findings and postoperative prognosis.
RESULTS: Postoperative survival was distinctly worse for patients with IN-IPMN than for patients with MI-IPMN, HGD-IPMN, and LGD/IGD-IPMN. Postoperative disease-specific 5-year survival rate was 100 % in patients with IN-IPMN, HGD-IPMN, and LGD/IGD-IPMN, by contrast, 40 % in patients with IN-IPMN. The presence of two of the three factors (pancreatitis, serum carbohydrate antigen [CA] 19-9 levels >13 U/mL, and mural nodules) could distinguish HGD-IPMN from LGD/IGD-IPMN with a sensitivity of 92.9 %, specificity of 90.2 %, positive predictive value of 76.5 %, negative predictive value of 97.4 %, and accuracy of 90.9 %.
CONCLUSIONS: To manage patients with BD-IPMN and achieve a good postoperative prognosis, surgical resection should be performed before progression to IN-IPMN.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25445160     DOI: 10.1007/s00423-014-1259-6

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  28 in total

1.  The carcinoembryonic antigen level in pancreatic juice and mural nodule size are predictors of malignancy for branch duct type intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Seiko Hirono; Masaji Tani; Manabu Kawai; Ken-ichi Okada; Motoki Miyazawa; Atsushi Shimizu; Yuji Kitahata; Hiroki Yamaue
Journal:  Ann Surg       Date:  2012-03       Impact factor: 12.969

2.  Outcomes following resection of invasive and noninvasive intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Keita Wada; Richard A Kozarek; L William Traverso
Journal:  Am J Surg       Date:  2005-05       Impact factor: 2.565

3.  Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma.

Authors:  F Maire; P Hammel; B Terris; F Paye; J-Y Scoazec; C Cellier; M Barthet; D O'Toole; P Rufat; C Partensky; E Cuillerier; P Lévy; J Belghiti; P Ruszniewski
Journal:  Gut       Date:  2002-11       Impact factor: 23.059

4.  An increase in the number of predictive factors augments the likelihood of malignancy in branch duct intraductal papillary mucinous neoplasm of the pancreas.

Authors:  Takao Ohtsuka; Hiroshi Kono; Yosuke Nagayoshi; Yasuhisa Mori; Kosuke Tsutsumi; Yoshihiko Sadakari; Shunichi Takahata; Katsuya Morimatsu; Shinichi Aishima; Hisato Igarashi; Tetsuhide Ito; Kousei Ishigami; Masafumi Nakamura; Kazuhiro Mizumoto; Masao Tanaka
Journal:  Surgery       Date:  2011-08-27       Impact factor: 3.982

5.  Clinical factors predictive of malignant and premalignant cystic neoplasms of the pancreas: a single institution experience.

Authors:  Natalie B Jones; Ioannis Hatzaras; Nathaniel George; Peter Muscarella; E Christopher Ellison; W Scott Melvin; Mark Bloomston
Journal:  HPB (Oxford)       Date:  2009-12       Impact factor: 3.647

6.  Branch-duct intraductal papillary mucinous neoplasms of the pancreas: to operate or not to operate?

Authors:  Roberto Salvia; Stefano Crippa; Massimo Falconi; Claudio Bassi; Alessandro Guarise; Aldo Scarpa; Paolo Pederzoli
Journal:  Gut       Date:  2006-11-24       Impact factor: 23.059

7.  Outcome of invasive and noninvasive intraductal papillary-mucinous neoplasms of the pancreas (IPMN): a 10-year experience.

Authors:  Marco Niedergethmann; Robert Grützmann; Ralf Hildenbrand; Dag Dittert; Niloufar Aramin; Melanie Franz; Frank Dobrowolski; Stefan Post; Hans-Detlev Saeger
Journal:  World J Surg       Date:  2008-10       Impact factor: 3.352

Review 8.  An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms.

Authors:  Ralph H Hruban; Kyoichi Takaori; David S Klimstra; N Volkan Adsay; Jorge Albores-Saavedra; Andrew V Biankin; Sandra A Biankin; Carolyn Compton; Noriyoshi Fukushima; Toru Furukawa; Michael Goggins; Yo Kato; Gunter Klöppel; Daniel S Longnecker; Jutta Lüttges; Anirban Maitra; G Johan A Offerhaus; Michio Shimizu; Suguru Yonezawa
Journal:  Am J Surg Pathol       Date:  2004-08       Impact factor: 6.394

9.  Minimally invasive intraductal papillary-mucinous carcinoma of the pancreas: clinicopathologic study of 104 intraductal papillary-mucinous neoplasms.

Authors:  Satoshi Nara; Kazuaki Shimada; Tomoo Kosuge; Yae Kanai; Nobuyoshi Hiraoka
Journal:  Am J Surg Pathol       Date:  2008-02       Impact factor: 6.394

10.  Malignant progression in IPMN: a cohort analysis of patients initially selected for resection or observation.

Authors:  J Lafemina; N Katabi; D Klimstra; C Correa-Gallego; S Gaujoux; T P Kingham; R P Dematteo; Y Fong; M I D'Angelica; W R Jarnagin; R K Do; M F Brennan; Peter J Allen
Journal:  Ann Surg Oncol       Date:  2012-10-31       Impact factor: 5.344

View more
  1 in total

Review 1.  Predictive performance of factors associated with malignancy in intraductal papillary mucinous neoplasia of the pancreas.

Authors:  M Heckler; L Brieger; U Heger; T Pausch; C Tjaden; J Kaiser; M Tanaka; T Hackert; C W Michalski
Journal:  BJS Open       Date:  2018-02-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.